HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer

SAN FRANCISCO — Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with advanced esophageal

January 20, 2024

China NMPA accepts Astellas BLA of zolbetuximab

Zolbetuximab is intended for treating patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma. Credit: meeboonstudio/Shutterstock.com. The Center for Drug Evaluation (CDE) of the China National

August 1, 2023

Understanding the risks for young mothers in child care proceedings

Mothers under the age of 20 are at the greatest risk of being involved in care proceedings in the 10 years after having their first

September 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.